Tundra Space

Tundra Space

Book DemoDirectoryLog InSign Up

Clinical Research Directory

Browse clinical research sites, groups, and studies.

SitesGroupsStudies
Back to Studies
ACTIVE NOT RECRUITING
NCT05795400
NA

Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy

Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

View on ClinicalTrials.gov

Summary

Efficacy and safety of early administration of the SGLT-2 inhibitor dapagliflozin will be evaluated in patients with HF, regardless of LVEF, due to amyloid cardiomyopathy.

Official title: Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy: a Pilot Study

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2022-06-01

Completion Date

2025-06

Last Updated

2025-03-04

Healthy Volunteers

No

Conditions

Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection FractionHeart Failure With Mid Range Ejection FractionAmyloid Cardiomyopathy

Interventions

DRUG

Dapagliflozin 10mg Tab

10 mg tablets given once daily, per oral use

DRUG

Placebo

tablet of placebo drug dosed once daily

Locations (1)

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Moscow, Russia